Loading...

Novartis AG

NVS•NYSE
Healthcare
Drug Manufacturers - General
$121.01
$1.00(0.83%)

Novartis AG (NVS) Stock Overview

Explore Novartis AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

A

Score: 82.2/100

Key Financials

Market Cap239B
P/E Ratio18.53
EPS (TTM)$6.38
ROE0.31%

AI Price Forecasts

1 Week$120.50
1 Month$120.86
3 Months$116.63
1 Year Target$118.25

NVS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novartis AG (NVS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $118.25.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 18.53 and a market capitalization of 239B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
10.85%
↑ 10.85%
Profit Growth
$6.53
↓ 19.59%
EPS Growth
$6.53
↓ 16.74%
Operating Margin
29.79%
↑ 48.88%
ROE
30.71%
↓ 19.59%
Dividend Yield
0.00%
↑ 8.81%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
1
Sell
1
Strong Sell
0

Price Targets

Low$118.00
Average$119.67
High$121.00

Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

CEO

Vasant Narasimhan

Employees

75,883

Headquarters

Lichtstrasse 35, Basel

Founded

1996

Frequently Asked Questions

;